Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment?

Alan, Özkan; Telli, Tuğba Akın; Aktaş, Bilge; Koca, Sinan; Ökten, İlker; Hasanov, Rahib; Başoğlu, Tuğba; Arıkan, Rukiye; Demircan, Nazım Can; Ercelep, Özlem; Kaya, Serap; Uğurlu, M. Ümit; Kaya, Hakan; Babacan, Nalân Akgül; Dane, Faysal; Yumuk, Perran Fulden

doi:10.1186/s12957-020-02019-y

Cited by 22 publications

(22 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Insulin resistance (IR) is a pathological condition that presents when a disturbance occurs in the biological response to insulin. IR is well known to raise the risk of metabolic diseases such as cancer ( 68 , 69 ). The possible mechanism for this association has fully been explained by Arcidiacono et al ( 68 ).…”

Section: Discussionmentioning

confidence: 99%

Association of High Dietary Acid Load With the Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies

et al. 2022

View full text Add to dashboard Cite

ObjectiveThis study aimed to determine the relationship between the high dietary acid load (DAL) and the risk of cancer.MethodsFive databases of PubMed, Web of Sciences, Scopus, Cochrane Library, and Google Scholar was searched to elicit original studies on humans, up to June 2021. Quality of the articles, risk of bias, and heterogeneity were assessed. A random-effects meta-analysis model was applied to estimate pooled effect size with a 95% confidence interval. Sensitivity analysis was performed using a fixed-effects model. Subgroup analyses were carried out based on gender, age, type of cancer, and type of DAL assessment indicator.ResultsSeventeen effect sizes from 10 articles were included in the analysis. Overall, individuals with the highest DAL were associated with a 66% increased risk of cancer compared to those with the lowest DAL (p < 0.001]. The risk of cancer increased 41% (p < 0.001) and 53% (p = 0.03) by high PRAL and NEAP, respectively. High DAL was associated with 32% (p < 0.001) and 79% (p < 0.001) increased risk of breast and colorectal cancers, respectively. High DAL was associated with 32% (p = 0.001) and 76% (p = 0.007) increased risk of cancer incident in women and men, respectively. The risk of cancer incident increased 35% (p < 0.001) and 49% (p < 0.001) at age ≤ and > of 50, respectively.ConclusionHigh DAL may be associated with a higher risk of cancer incidence not only in the whole studied population but also across cancer types, both genders, both DAL assessment indicators, and also among both high- and low-risk age groups for cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Association of High Dietary Acid Load With the Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Interestingly, a high systemic immune-inflammation index has been reported to predict the poor prognosis of BC patients as a promising indicator [ 32 ]. In addition, absolute lymphocyte count and insulin resistance have been reported to be served as predictors for chemotherapy response [ 33 , 34 ]. Tang et al have successfully developed a nomogram to predict pathological complete response after neoadjuvant chemotherapy of ER-positive and HER2-negative BC patients [ 35 ].…”

Section: Discussionmentioning

confidence: 99%

Overexpressed VDAC1 in breast cancer as a novel prognostic biomarker and correlates with immune infiltrates

et al. 2022

View full text Add to dashboard Cite

Background More and more evidence suggests that cancer is a mitochondrial metabolic disease recently and mitochondria dysfunction is critical to tumorigenesis. As a gatekeeper of mitochondria, the voltage-dependent anion channel 1 (VDAC1) is associated with the development of breast cancer (BC). However, its potential mechanism and clinical significance remain unclear; thus, in this research, we aimed to explore it. Methods VDAC1 expression in BC tissues and normal tissues was obtained from The Cancer Genome Atlas (TCGA) and validated by datasets from the gene expression omnibus (GEO) database. Then, the relationships between VDAC1 expression and clinicopathological features were analyzed. Receiver operating characteristics (ROC) curves were used to identify the diagnostic value of VDAC1. The prognostic value was evaluated by Kaplan-Meier survival curves and Cox regression analysis. VDAC1 with its co-expression genes were subjected to enrichment analysis to explore potential mechanisms in BC and the protein-protein interaction (PPI) network was constructed. At last, the association between VDAC1 expression and infiltration levels of immune cell infiltration by various methods, as well as their corresponding markers, was analyzed. We also analyzed the correction between VDAC1 expression and eight immune checkpoint genes and the tumor immune dysfunction and exclusion (TIDE) scores of each BC sample in TCGA were calculated and the differences between high and low VDAC1 expression groups were analyzed. Results VDAC1 expression was remarkably elevated in BC (p < 0.001), and high expression of VDAC1 was associated with the positive expression of ER (p = 0.004), PR (p = 0.033), and HER2 (p = 0.001). ROC analysis suggested that VDAC1 had diagnosed value in BC. The Kaplan-Meier analysis suggested that higher expression of VDAC1 was associated with shorter overall survival (OS), and further Cox regression analysis revealed that VDAC1 was an independent factor of unfavorable prognosis in BC patients. Enrichment analysis of VDAC1 and its co-expression suggested that VDAC1 was related to the regulation of mitochondrial energy metabolism and protein modification, and the HIF-1 singing pathway might be the potential mechanism in BC. Notably, we found that VDAC1 expression was infiltration levels of most types of immune cells, as well as the expression of marker genes of immune cells. The ICGs PDCD1, CTLA4, LAG3, SIGLEC15, and TIGIT were negatively corrected with VDAC1 expression in BC. TIDE scores between the low and high expression groups showed no difference. Conclusion Overexpressed VDAC1 in BC could be severed as a novel biomarker for diagnosis and VDAC1 was an independent factor for adverse prognosis prediction. Our study revealed that VDAC1 might inhibit tumor immunity and might be a novel therapeutic target in BC.

show abstract

“…Thirteen (54.5%) patients had insulin resistance associated with a higher BMI, triglyceride, and fasting glucose level compared to patients without insulin resistance. As a result of this study, the probability of having a pathological complete response (pCR) after neo-adjuvant therapy in patients with insulin resistance was lower compared to those without insulin resistance, suggesting a possible negative effect of insulin resistance on pCR following neoadjuvant therapy, particularly with hormone-positive and Her-2 negative cases of non-diabetic BC [ 34 ].…”

Section: Host Metabolism and Breast Cancer Prognosismentioning

confidence: 99%

Insulin/IGF Axis in Breast Cancer: Clinical Evidence and Translational Insights

Biello

Platini²,

D’Avanzo³

et al. 2021

Biomolecules

View full text Add to dashboard Cite

Background: Breast cancer (BC) is the most common neoplasm in women. Many clinical and preclinical studies investigated the possible relationship between host metabolism and BC. Significant differences among BC subtypes have been reported for glucose metabolism. Insulin can promote tumorigenesis through a direct effect on epithelial tissues or indirectly by affecting the levels of other modulators, such as the insulin-like growth factor (IGF) family of receptors, sex hormones, and adipokines. The potential anti-cancer activity of metformin is based on two principal effects: first, its capacity for lowering circulating insulin levels with indirect endocrine effects that may impact on tumor cell proliferation; second, its direct influence on many pro-cancer signaling pathways that are key drivers of BC aggressiveness. Methods: In the present review, the interaction between BC, host metabolism, and patients’ prognosis has been reviewed across available literature evidence. Conclusions: Obesity, metabolic syndrome, and insulin resistance are all involved in BC growth and could have a relevant impact on prognosis. All these factors act through a pro-inflammatory state, mediated by cytokines originated in fat tissue, and seem to be related to a higher risk of BC development and worse prognosis.

show abstract

Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment?

Cited by 22 publications

References 51 publications

Association of High Dietary Acid Load With the Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies

Association of High Dietary Acid Load With the Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies

Overexpressed VDAC1 in breast cancer as a novel prognostic biomarker and correlates with immune infiltrates

Insulin/IGF Axis in Breast Cancer: Clinical Evidence and Translational Insights

Contact Info

Product

Resources

About